PRESS RELEASE: Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth

Sanofi-aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth

PARIS, Sept. 17, 2007--Sanofi-aventis today made announced it plans to have 31 potential submissions by the end of 2010. The company released a detailed analysis on its pipeline.

Significant progress in pipeline

  • Important clinical results and 31 potential submissions by the end of 2010.
  • 48 projects in advanced phases (phase IIb/III).
  • A well balanced portfolio between our major therapeutic areas.

High-potential projects in our spheres of excellence


Possible successor to Lovenox® and an alternative to antivitamin K

AVE5026 (new ultra low molecular weight heparin): Phase IIb results demonstrated potentially greater efficacy than Lovenox® with a comparable safety profile. Large-scale phase III program to start. Anticoagulant with best-in-class potential.

Biotinylated idraparinux (selective, neutralizable factor Xa synthetic inhibitor): Comparative study versus anti-vitamin K due to start at end 2007 targeting a major clinical need in anti-coagulation – prevention of stroke and systemic embolism in cases of atrial fibrillation.


A portfolio that targets all stages of the disease while offering relevant solutions for concomittant comorbidities, in particular overweight

Rimonabant (the first CB1 antagonist): Significant expansion of the clinical program in type 2 diabetes, with more than 5,700 patients, including a comparative study versus the most recently-approved type 2 diabetes treatment due to start in the first quarter of 2008. Worldwide submission in this indication scheduled for 2009.

AVE0010 (GLP-1 agonist): Very encouraging phase IIb results. Once a day injection demonstrated efficacy. Start of a phase III program in the first half of 2008. Prolonged release formulation due to start phase II trials in the first half of 2008.

AVE2268 (SGLT-2 inhibitor): Ideal profile for use in combination with other anti-diabetics. Phase IIb results due in the first half of 2008, followed by rapid start of phase III.

Please see the attachment for the complete press release.

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.